587 related articles for article (PubMed ID: 27981497)
1. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Iijima H; Kifuji T; Maruyama N; Inagaki N
Adv Ther; 2015 Aug; 32(8):768-82. PubMed ID: 26280756
[TBL] [Abstract][Full Text] [Related]
3. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
4. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
[TBL] [Abstract][Full Text] [Related]
5. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
[TBL] [Abstract][Full Text] [Related]
6. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
7. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
8. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
Kario K; Hoshide S; Okawara Y; Tomitani N; Yamauchi K; Ohbayashi H; Itabashi N; Matsumoto Y; Kanegae H
J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1527-1535. PubMed ID: 30246286
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
[TBL] [Abstract][Full Text] [Related]
10. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
11. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
Alba M; Xie J; Fung A; Desai M
Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
[TBL] [Abstract][Full Text] [Related]
12. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Qiu R; Balis D; Xie J; Davies MJ; Desai M; Meininger G
Curr Med Res Opin; 2017 Mar; 33(3):553-562. PubMed ID: 27977934
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
Devineni D; Polidori D
Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
[TBL] [Abstract][Full Text] [Related]
14. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Barsotti E; Clerico A; Muscelli E
Diabetes Care; 2017 Jun; 40(6):771-776. PubMed ID: 28325783
[TBL] [Abstract][Full Text] [Related]
15. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Adachi J; Inaba Y; Maki C
Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
[TBL] [Abstract][Full Text] [Related]
16. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
[TBL] [Abstract][Full Text] [Related]
18. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
19. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Weir MR; Kline I; Xie J; Edwards R; Usiskin K
Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
